Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend
Alexion, AstraZeneca plc’s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III...
Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data
Sanofi S.A. (NASDAQ: SNY) announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal...
Roche’s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for...
Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia
Home Control International Limited (HKG: 1747) announced it has entered into a strategic memorandum of...
Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia
Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (“Tempo Scan”) announced the...
Sichuan Biokin’s HER2 ADC T-Bren Enters Phase III Trial for Biliary Tract Cancer After Platinum Failure
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its self-developed innovative biologic drug, T-Bren...
Gilead’s Trodelvy Receives Positive CHMP Opinion for First-Line TNBC Treatment in Combination with Keytruda
Gilead Sciences Inc. (NASDAQ: GILD) announced that the Committee for Medicinal Products for Human Use...
Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification
Walvax Biotechnology Co., Ltd. (SHE: 300142) announced today that its bivalent human papillomavirus (HPV) vaccine...
Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance
Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced on July 23, 2026 that China’s National...
Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136
Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced today that its subsidiary GeneScience Pharmaceuticals...
Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market
Eli Lilly and Company (NYSE: LLY) announced on July 23, 2026 positive topline results from...
Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA: 688488) announced today that China’s National Medical Products...
Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth
Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending...
Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that...
Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that China’s National Medical...
Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July...
Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform
Nona Biosciences announced on July 23, 2026 a strategic research collaboration with the Medical University...
Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub
Private enterprises from Pakistan and China have signed nine pharmaceutical sector agreements valued at approximately...
AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial
AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah...
MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG: 2252) issued a positive profit alert announcing its...